Michael Ehlers
Neuroscience Chief Scientific Officer
Pfizer
From this contributor
A cautionary tale for autism drug development
Poorly designed animal drug studies for motor disorders have led to spurious conclusions for the clinical trials that follow. This may be even more true for autism research, says Michael Ehlers.
SHANK mutations converge at neuronal junctions in autism
SHANK3, one of the strongest candidate genes for autism, has the potential to be a molecular entry point into understanding the synaptic, developmental and circuit origins of the disorder.
SHANK mutations converge at neuronal junctions in autism
Drug zone
Rodent and stem cell models remain challenging for developing psychiatric drugs, says Michael Ehlers, chief scientific officer of neuroscience at Pfizer.
Explore more from The Transmitter
Diverse autism genes derail common developmental pathways
Multiple genetic mouse models initially show delayed cortical development, but the animals’ molecular trajectories diverge within weeks after birth, a new study finds.
Diverse autism genes derail common developmental pathways
Multiple genetic mouse models initially show delayed cortical development, but the animals’ molecular trajectories diverge within weeks after birth, a new study finds.
Brain’s sex differences are subtle and contradictory, large MRI study finds
Sex-based behavioral differences do not match with variations in brain activation or structure in a study of almost 1,000 people.
Brain’s sex differences are subtle and contradictory, large MRI study finds
Sex-based behavioral differences do not match with variations in brain activation or structure in a study of almost 1,000 people.
A consensus on the definition of profound autism, and more
Here is a roundup of autism-related news and research spotted around the web for the week of 5 July.
A consensus on the definition of profound autism, and more
Here is a roundup of autism-related news and research spotted around the web for the week of 5 July.